J. Woollard

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.